Growth hormone, prolactin, and sexuality

Area of Science:

• Endocrinology
• Neuroendocrinology
• Sexual Medicine

Background:

• Growth hormone (GH) and prolactin (PRL) are not classical sex hormones but play significant roles in endocrine control of sexual function.
• PRL modulates central nervous system pathways (dopaminergic, serotoninergic) influencing sexual behavior and arousal, with levels rising post-orgasm.
• Chronic hyperprolactinemia is linked to hypogonadotropic hypogonadism and sexual dysfunction, often reversible with treatment.

Purpose of the Study:

• To explore the physiological roles of GH and PRL in male and female sexual function.
• To investigate the impact of hyperprolactinemia, hypoprolactinemia, and GH disorders (deficiency and excess) on sexual health.
• To assess the effects of hormonal treatments on sexual function in affected individuals.

Main Methods:

• Review of existing literature on GH, PRL, and sexual function.
• Analysis of clinical associations between hormone levels and sexual dysfunction.
• Examination of treatment outcomes for hormonal imbalances affecting sexual health.

Main Results:

• PRL impacts central sexual control and peripheral erectile mechanisms; hyperprolactinemia causes sexual dysfunction, while hypoprolactinemia may risk erectile dysfunction.
• GH influences the hypothalamus-pituitary-gonadal axis and genital sexual response; GH deficiency or excess is associated with decreased libido and arousal, and erectile dysfunction in men.
• Treatment of hyperprolactinemia and GH imbalances can improve sexual function, though the exact mechanisms and extent of benefit require further elucidation.

Conclusions:

• GH and PRL are crucial, though often overlooked, regulators of sexual function in both sexes.
• Hormonal imbalances like hyperprolactinemia and GH disorders significantly impair sexual health, necessitating targeted therapeutic interventions.
• Further research is needed to fully clarify the direct roles of GH and PRL in sexual function and the precise benefits of their replacement or normalization therapies.